DAM
PRTK

DLD Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

DLD Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-248,406
Closed -$4.78M – 101
2017
Q1 		$4.78M Buy
248,406
+238,116
+2,314% +$3.75M 0.77% 22
2016
Q4 		$158K Buy
+10,290
New +$134K 0.05% 65

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

DLD Asset Management's PRTK Position: Q2 2017 in Review

DLD Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2017, closing a stake of 248,406 shares — an estimated $4.78M sold.

DLD Asset Management first reported a position in PRTK in Q4 2016 and held it in 2 quarters. The position peaked at $4.78M in Q1 2017. 119 funds tracked by Wall St. Rank hold PRTK as of Q2 2017.

  • DLD Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • DLD Asset Management sold 248,406 Paratek Pharmaceuticals, Inc. shares in Q2 2017, an estimated $4.78M.
  • DLD Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • DLD Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $4.78M in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2017.

Based on DLD Asset Management's 13F filing for Q2 2017, filed 11 Aug 2017.